Top 20 global biopharma companies report 3.4% fall in market cap in Q1 2023: GlobalData

Bayer reported the highest market capitalization growth of 23.1% during Q1 2023

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards

Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData

Several late-stage pipeline products have the potential to address some of these unmet needs

Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline

Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology

FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression

AI-backed innovations to drive Australia ultrasound systems market, says GlobalData

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Newly patented bone marrow biopsy device to bolster bone cancer treatment in India, says GlobalData

It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone

FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients

GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme

SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties